08:00 , Dec 8, 2014 |  BC Week In Review  |  Financial News

Bioheart financial update

Bioheart Inc. (OTCQB:BHRT), Sunrise, Fla.   Business: Cardiovascular, Gene/Cell therapy   Date announced: 2014-10-24   Note: Bioheart entered into a two-year stock purchase agreement with Magna Equities for up to $3 million.  ...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Bioheart gene/cell therapy news

Last month, Bioheart opened its South African Stem Cell Institute (SASCI) laboratory and clinic in South Africa. At least 12 patients underwent autologous cell therapies in September for a variety of conditions, including spinal cord...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

AdipoCell: Clinical trial started

Bioheart began an open-label, U.S. clinical trial to evaluate IV AdipoCell in up to 100 patients with COPD. Bioheart is evaluating AdipoCell in a Phase I trial in patients with degenerative disc disease and has...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

AdipoCell: Clinical trial started

Bioheart began an open-label, U.S. clinical trial to evaluate intra-discally injected AdipoCell in up to 100 patients with degenerative disc disease. AdipoCell has completed a Phase I trial for congestive heart failure (CHF). Last year,...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

AdipoCell: Additional Phase I data

Additional data from the Mexican Phase I ANGEL trial in 5 CHF patients showed that AdipoCell injection led to an average improvement of 6MWT of 68 meters from baseline to 6 months. Additionally, 80% of...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Bioheart, Magnum Cell Therapies deal

Bioheart partnered with Magnum to provide Bioheart's autologous cellular therapies to patients living in Honduras as well as to medical tourists. Bioheart will provide training to Magnum and will take a 10% ownership stake in...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Bioheart deal

Bioheart acquired exclusive rights to three cellular-based immunotherapy patents for use in all aspects of veterinary medicine from inventor Allan Wu for an undisclosed amount. The company said Wu has invented a method of immunotherapy...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Bioheart, Global Stem Cells Group Inc. sales and marketing update

The companies partnered to provide Bioheart's therapies and products to Global Stem's network of physicians and qualified patients. Under the deal, Global Stem will also train additional physicians in Bioheart's regenerative medicine techniques while contributing...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Adipose-derived stem cells: Preliminary Phase I data

Preliminary data from the Mexican Phase I ANGEL trial in 5 CHF patients showed that AdipoCell injection was safe and led to an average improvement in 6MWT of 47 meters from baseline to 3 months....
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

Bioheart, Invitrx deal

Invitrx granted Bioheart rights to Invitrx's adipose derived stem cell products for use in all indications in humans and animals. Bioheart intends to use these techniques to advance the development and commercialization of its AdipoCell...